Novartis Venture Fund — Full Portfolio

BiotechCambridge, US

Manuel Aivado(Executive Officer)Enrico Petrillo(Director)

BoardCaleb Winder(Director)inSeth L. Harrison(Director)Reinhard J. Ambros(Director)Joseph A. Yanchik III(Executive Officer, Director)in

Co-investorsExcel Venture Management

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.

BiotechHealthtechMedical DevicesMelbourne, AU

Sara Prickett(Co-founder)

Co-investorsTenmileBreakthrough VictoriaUniSeed Pty Ltd.

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)David Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)Tom Wickham(Chief Scientific Officer)

Co-investorsOrbiMedJDRF T1D FundRA Capital

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)

Co-investorsSanofi VenturesForbionVersant Ventures

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.

BiotechDeep TechMedical DevicesBurlington, US

KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)

BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)

Co-investorsDroia VenturesEisai Innovation, Inc.RA Capital

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

David Zacks(Co-Founder & Chief Scientific Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)John K Freshley(Executive Officer, Director)Jeffrey A Jamison(Executive Officer)David N Zacks(Executive Officer, Director)

Co-investorsExSight VenturesInvest MichiganVisionary VenturesBios PartnersInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.

BiotechDigital HealthMedical DevicesBasel, CH

Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)Katherine High(CEO)

Co-investorsARCH Venture PartnersBioGeneration VenturesF-Prime CapitalGV (Google Ventures)

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Co-investorsRoche Venture FundSanofi VenturesYsios CapitalAsabys PartnersCriteria Bio VenturesNew Enterprise Associates (NEA)+2 more

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHealthCapKurma PartnersRoche Venture FundYsios CapitalColumbus Venture PartnersEurazeo+1 more

West Hills, US

Board seatMichal Silverberg· per SEC Form D · $5.5M raise · filed Aug 2020

Co-investorsDecheng CapitalRMGP Biopharma Investment FundvenBio Global Strategic

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Board seatAnja Koenig· per SEC Form D

Co-investorsLongwood FundMission BiocapitalOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLCSofinnova Partners+2 more

Co-investorsMPM BioImpactSV Health InvestorsUCL Technology Fund

Alesta Therapeutics is a biotech company developing oral small molecule therapies for rare diseases with limited treatment options.

BiotechHealthtech

Co-investorsDroia VenturesFrazier Life SciencesFrazier Healthcare PartnersRTW Investments L.P.Thuja Capital

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)Giles Brown(Executive VP Drug Discovery)

Co-investorsAdvent Life SciencesSV Health InvestorsDementia Discovery FundEuropean Investment FundForbionGilde Healthcare+1 more

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsPfizer Venture InvestmentsPontifax Venture Capital

Co-investorsM VenturesRA Capital

Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043).

BiotechHealthtech

Co-investorsAndera PartnersM VenturesPfizer Venture InvestmentsRA CapitalSofinnova PartnersSV Health Investors

Co-investorsSV Health Investors

Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.

BiotechHealthtech

Co-investorsF-Prime CapitalRiverVest Venture PartnersSanofi Venturesabrdn plcEQT Life Sciences

Creates gene therapies that integrate therapeutic genes into patients' genomes to treat genetic disorders.

HealthtechWatertown, US

Thomas Barnes(Chief Executive Officer/President)Richard Morris(Chief Financial Officer)

BoardRoy Amariglio(Director)Nick Olsen(Director)Stephen Squinto(Director)inMichal Silverberg(Director)

Co-investorsDeep InsightOrbiMed

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechMedical Devices

Thomas M. Barnes(CEO & Board Member)

Co-investorsDeep InsightDelos CapitalOrbiMed

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a protein it identified as a cancer therapy resistance mechanism, aiming to restore anti-tumor immune activity and improve responses to checkpoint inhibitors.

BiotechHealthtech

Co-investorsBayern KapitalCanaan PartnersJeito CapitalBioGeneration VenturesBioqube Ventures

Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa.

BiotechHealthtechMedical DevicesOss, NL

Co-investorsBOMCurie CapitalPureos BioventuresBioGeneration VenturesForbion

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)

Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalRoche Venture FundSamsara BioCapitalTaiho Ventures, LLC+3 more

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.

BiotechHealthtech

Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)Cristina Oliva(Chief Medical Officer)Nick Robbins-Cherry(Chief Financial Officer)Elizabeth Hardaker(Chief Translational Science Officer)

Co-investors3B Future Health FundAlbionVCEpidarex CapitalGlobal BioAccess FundUCL Technology FundBioGeneration Ventures

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian

Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalCasdin Capital

BiotechDel Mar, US

Matthew Disney(Director)Paul Stone(Executive Officer)inYujiro Hata(Director)Kevin Forrest(Executive Officer, Director)

BoardScott Rocklage(Executive Officer, Director)inJason Hafler(Director)in

Co-investors5AM VenturesKleiner PerkinsSanofi Ventures

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.

BiotechHealthtech

Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova Partners+3 more

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsLG Technology VenturesOrbiMedPontifax Venture CapitalWindham Capital PartnersMedicxiSymBiosis

Provides functional information about mutations and drug responses to enable precision oncology treatments.

Co-investorsSR One Capital ManagementWindham Capital Partners

FoRx Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs that target DNA replication stress in treatment-resistant cancers.

BiotechDeep TechHealthtechBasel, CH

Co-investorsM VenturesPfizer Venture Investments

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

BoardLaura Brass(Director)inKai Wucherpfennig(Director)

Co-investorsDC Investment PartnersLongwood FundMedical Excellence CapitalOno Venture Investment, Inc.Solasta VenturesAgent Capital+2 more

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)Kees Been(Chief Executive Officer)inJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYsios CapitalForbionSunstone Capital

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in

Co-investorsSV Health InvestorsDementia Discovery FundForbion

NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore.

BiotechHealthtechLongevity

Co-investorsCriteria Bio VenturesM VenturesSV Health InvestorsBritish Business BankDementia Discovery Fund

Peptone develops a product engine to design small-molecule drug candidates targeting intrinsically disordered proteins, which have been difficult to address with conventional drug discovery approaches.

AI & Machine LearningBiotechDeep Tech

Co-investorsBessemer Venture PartnersHoxton VenturesWalden CatalystF-Prime CapitalFounders FactoryFounders Factory NY

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

Pablo Rojas(Founder)in

Co-investorsY CombinatorForbionGlilot Capital PartnersOmega FundsYK Bioventures

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US

Co-investorsDroia VenturesDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpactVida Ventures+1 more

Rappta Therapeutics develops a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor enzyme PP2A (protein phosphatase 2A).

BiotechHealthtech

Co-investorsAdvent Life SciencesNovo Holdings

Co-investorsF-Prime Capital

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieThe Column Group

SIP Basel Area provides move-in ready wetlabs and serviced offices with flexible contracts, ranging from single benches and hot desks to turnkey labs and headquarters.

BiotechPropTech

Advancing precision bispecific antibody-drug conjugates to treat cancer

Co-investorsDCVC (Data Collective)DCVC BioFrazier Life Sciences

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

BiotechHealthtechMedical DevicesSan Diego, US

Eric Murphy(Chief Executive Officer, Co-Founder, & Director)

Co-investorsAstellas Venture Management LLCFrazier Life SciencesLongwood FundOrbiMedInsight Partners

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBifLightstone VenturesNew Enterprise Associates (NEA)Ysios CapitalGilde HealthcareOost NL

HealthtechLexington, US

Simon Williams(Executive Officer, Director)John Hartnett(Executive Officer)

BoardRichard B. Emmitt(Director)Edward M. Giles(Director)Anthony J. Sinskey(Director)

Co-investorsThe Vertical Group